Next 10 |
home / stock / inm / inm articles
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern a...
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern arou...
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. BlackBerry reported qua...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Li...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 200 points on Tuesday. The Dow traded up 0.67% to 33,155...
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's ...
U.S. stocks traded slightly higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to...
InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading higher Tuesday after the company said it selected a lead Alzheimer's drug candi...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (&...
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition ...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signal...